Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01078441 · OUTCOME

One-year Survival in Patients Treated With This Regimen.

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant · Source last updated 2015-01-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Proportion of patients
Interval / dispersion
90% Confidence Interval
Time frame
Assessed at 1 year

What was measured

Proportion of patients who are still alive at 1 year after registration.

Analysis population: All eligible and treated patients are included in this analysis.

Groups in this outcome

Treatment (Combination Chemotherapy)

Patients receive bortezomib subcutaneously on days 1, 8, and 15; liposomal doxorubicin intravenously (IV) over 1 hour on day 4; oral dexamethasone on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. liposomal doxorubicin: Given IV bortezomib: Given subcutaneously. dexamethasone: Given orally cyclophosphamide: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Combination Chemotherapy)2

Reported measurements

Source class 1
Values in Proportion of patients · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (Combination Chemotherapy)0.5Not reported0.030.97Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.03
        upper Limit
        0.97
        value
        0.5
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    units
    Participants
description
Proportion of patients who are still alive at 1 year after registration.
dispersion Type
90% Confidence Interval
groups
  1. description
    Patients receive bortezomib subcutaneously on days 1, 8, and 15; liposomal doxorubicin intravenously (IV) over 1 hour on day 4; oral dexamethasone on days 1, 2, 8, 9, 15 and 16; and cyclophosphamide IV over 2 hours on day 1. Treatment repeats every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. liposomal doxorubicin: Given IV bortezomib: Given subcutaneously. dexamethasone: Given orally cyclophosphamide: Given IV
    id
    OG000
    title
    Treatment (Combination Chemotherapy)
param Type
NUMBER
population Description
All eligible and treated patients are included in this analysis.
reporting Status
POSTED
time Frame
Assessed at 1 year
title
One-year Survival in Patients Treated With This Regimen.
type
PRIMARY
unit Of Measure
Proportion of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice